Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 7/20 | 0.33 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.33 |
| ▸ | PI4KA | P42356 | 1/20 | 0.33 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913707 | 0.83 | PDE1B (0.33) | PDE1BPIK3CDPIK3CAPIK3CBPI4KA | |
| SCHEMBL5031810 | 0.81 | HRH3 (0.34) | NPC1POLBRAB9APDE1BPIK3CD | |
| SCHEMBL23308884 | 0.76 | PIK3CD (0.37) | POLBRAB9AFYNPIK3CDPIK3CA | |
| SCHEMBL3864978 | 0.76 | PPARG (0.38) | NPC1POLBRAB9APDE1B | |
| SCHEMBL16422702 | 0.75 | ALDH1A1 (0.44) | NPC1POLBRAB9A | |
| SCHEMBL16892170 | 0.75 | NPC1 (0.41) | NPC1POLBRAB9ACYSLTR1PIK3CD | |
| SCHEMBL4140258 | 0.73 | CCR1 (0.41) | NPC1POLBRAB9ACYSLTR1FYN | |
| SCHEMBL20302030 | 0.73 | HRH3 (0.33) | — | |
| SCHEMBL1373687 | 0.72 | HRH3 (0.42) | NPC1POLBRAB9ACYSLTR1HSD17B10 | |
| SCHEMBL2881587 | 0.72 | NPC1 (0.37) | NPC1POLBRAB9ACYSLTR1FYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-7547700-B2 | Aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2009-06-16 | — | — | US | disclosed |
| EP-1539738-B1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2009-03-04 | — | — | EP | disclosed |
| EP-1539738-B1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL -PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PF MEDICAMENT (FR) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | PIERRE FABRE MEDICAMENT (FR) | 2006-05-11 | — | — | US | disclosed |
| EP-1539738-A1 | NOVEL ARYL- 4-HALO-4- HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL -METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2005-06-15 | — | — | EP | disclosed |
| WO-2003106449-A1 | NOVEL ARYL-{4-HALO-4-[HETEROARYLMETHYLAMINO)-METHYL]-PIPERIDIN-1-YL}-METHANONE DERIVATIVES, METHODS FOR PRODUCTION AND USE THEREOF AS MEDICAMENTS | PIERRE FABRE MEDICAMENT (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100244-A1 | Novel aryl-[4-halo-4(heteroarylmethylamino)-methyl]-piperidin-1-1yl]-methanone derivatives, methods for production and use thereof as medicaments | CYP4B1, CYP4X1, CYP2E1 | NPC1 468/4885POLB 1909/4885RAB9A 4098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.